Asia-Pacific preventive inhaler market is anticipated to grow at a substantial growth rate of around 3.8% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The preventive inhaler market in the Asia-Pacific region presents future opportunities for growth as the prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing the geriatric population specially in Japan is another major reason for the growing market for preventive inhalers.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-preventive-inhaler-market
The Asia-Pacific preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device type, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the Asia-Pacific preventive inhaler market due to providing an easy inhalation solution. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/asia-pacific-preventive-inhaler-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the Asia-Pacific preventive inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, Propeller Health, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access to life-changing medicines in India.
Market Segmentation
Asia-Pacific Preventive Inhaler Market by Device Type
- Metered Dose Inhaler
- Dry Powder Inhaler
Asia-Pacific Preventive Inhaler Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Asia-Pacific Preventive Inhaler Market by End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- China
- Japan
- India
- Rest of Asia-Pacific
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- Aradigm Corp.
- AstraZeneca PLC
- Beximo Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- GlaxoSmithKline PLC
- Koninklijke Philips N.V.
- MidasCare Pharmaceutical Pvt. Ltd.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Sunovion Pharmaceuticals
- Teijin Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
